1. Fact sheet for Healthcare Providers Administering Vaccine (Vaccination Providers). 2021. FDA. https://www.fda.gov/media/144413/download
2. Fact sheet for health care providers emergency use authorization (EUA) of Comirnaty. 2021. Pusat Informasi Obat Nasional. http://pionas.pom.go.id/sites/default/files/obat_baru/Fact%20Sheet%20For%20Health%20Care_%28Bahasa%20Inggris%29_Comirnaty%20Suspensi%20Injeksi%20225%20mcg_MRNA%20OF%20SARS-COV%202%20VIRUS%20SPIKE%20PROTEIN_EUA2108602043A1%20%26%20EUA2155900143A1_2021.pdf
4. Lembar Fakta untuk Penyedia Pelayanan Kesehatan Izin Penggunaan dalam Keadaan Darurat Comirnaty. 2021. Pusat Informasi Obat Nasional. http://pionas.pom.go.id/sites/default/files/obat_baru/Fact%20Sheet%20For%20Health%20Care_%28Bahasa%20Indonesia%29_Comirnaty%20Suspensi%20Injeksi%20225%20mcg_MRNA%20OF%20SARS-COV%202%20VIRUS%20SPIKE%20PROTEIN_EUA2108602043A1%20%26%20EUA2155900143A1_2021.pdf
16. Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity (MOSAIC). 2021. ClinicalTrials.gov identifier NCT04894435. https://clinicaltrials.gov/ct2/show/NCT04894435
17. Hillus D, Schwarz T, Tober L, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. 2021. The Lancet. https://doi.org/10.1016/S2213-2600(21)00357-X
34. Borobia et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet. June 2021.
36. Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature medicine. 2021 Available from: https://www.nature.com/articles/s41591-021-01449-9.pdf